指南針(300803.SZ):麥高證券2022年8-12月淨利潤已實現扭虧為盈
格隆匯5月11日丨有投資者在投資者互動平台向指南針(300803.SZ)提問,“貴司現在屬於互聯網券商嗎?據悉貴司收購的證券目前就開始扭虧為盈利了,是否屬實?”
指南針回覆稱,公司自去年7月29日接手麥高證券後,立即着手恢復其各項業務發展,逐步加大人員建設和研發投入。根據審計財務數據,麥高證券2022年8-12月營業利潤仍處於虧損狀態,但考慮到麥高證券存在尚未到期的企業所得税可彌補虧損,公司基於會計準則的規定,根據盈利預測情況確認相應規模的遞延所得税資產。由此,麥高證券2022年8-12月淨利潤已實現扭虧為盈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.